SHSamuli Hirsjärvi

Samuli Hirsjärvi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Samuli Hirsjärvi has a total of 3 co-authors. Here are the top co-authors by number of shared publications:

  • Heikki Vilhonen

    University of Turku, Department of Pulmonary Diseases and Clinical Allergology and Division of Medicine, Department of Pulmonary Diseases, Turku University Hospital, Hämeentie 11, 20521 Turku, Finland

    1 shared publication
  • Samu Kurki

    Auria Biobank, University of Turku, and Turku University Hospital, 20521 Turku, Finland

    1 shared publication
  • Tarja Laitinen

    Department of Pulmonary Diseases, Division of Medicine, Turku University Hospital and University of Turku, Turku, Finland

    1 shared publication

Latest Publications

  • Open Access

    Retrospective Evaluation of Lung Adenocarcinoma Patients Progressing on 1st Line Chemotherapy

    by Heikki Vilhonen, Samu Kurki, Tarja Laitinen, Samuli Hirsjärvi

    Background and Objectives: Evaluation of data from electronic health care records could help in guiding towards more rational drug treatments. This single center study evaluated clinical characteristics that could be associated with disease progression. Methods: This was a real world data (RWD) study using existing data from the registries of a university hospital. Patients had lung adenocarcinoma and they had received 1st line treatment. Treatment patterns and survival parameters were characterized and clinical characteristics of the patients were evaluated together with their association with disease progression. Results: 80 stage III/IV patients fulfilling inclusion criteria were identified. Mean age was 62 years and 61% were men. In total, 65% were current smokers and 82% had performance status (ECOG) 0/1. Median progression free survival (mPFS) and median overall survival (mOS) for stage III and IV patients were 8.5 and 5.4 months, and 21.9 and 8.6 months, respectively. The study found that 69% of patients progressed within 9 months from the start of the 1st line treatment. Poor performance status (ECOG 3), male gender, and smoking suggested faster disease progression. Most had received cis/carboplatin-based treatment in the 1st line. Cisplatin regimens were associated with more complete responses and better PFS and OS than the carboplatin ones. Conclusions: By combining algorithmic and manual validation of electronic health care records, clinically valid characteristics and outcomes could be evaluated and presented. This approach forms a basis for tools such as quality registries that can guide treatment decisions.